Publications by authors named "Jimenez-Cauhe J"
Low-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series.
Actas Dermosifiliogr
November 2024
Article Synopsis
- * Out of 122 patients, 45.1% reported subjective improvements in hair density at the frontotemporal hairline, with varying degrees of improvement noted.
- * While 57.4% of patients saw overall hair density improvements, 33.6% experienced adverse effects, primarily hypertrichosis; however, the findings suggest that oral minoxidil can enhance hair and eyebrow growth in FFA patients.
Background: Androgenetic alopecia (AGA) is common. While topical minoxidil remains the only FDA-approved therapeutic for AGA, its efficacy is limited in stimulating clinically significant hair regrowth over the longer term. Oral minoxidil, which is used off-label, is a promising alternative; however, its effectiveness and underlying mechanisms warrant further investigation.
View Article and Find Full Text PDFBackground And Objective: Systemic adverse effects (AE) are a major concern of low-dose oral minoxidil (LDOM) treatment, especially in patients with arterial hypertension or arrhythmia. The objective of this study was to evaluate the safety of LDOM in patients with hypertension or arrhythmia.
Patients And Methods: Retrospective multicenter study of patients with hypertension or arrhythmia treated with LDOM for any type of alopecia.
Background And Objective: Systemic adverse effects (AE) are a major concern of low-dose oral minoxidil (LDOM) treatment, especially in patients with arterial hypertension or arrhythmia. The objective of this study was to evaluate the safety of LDOM in patients with hypertension or arrhythmia.
Patients And Methods: Retrospective multicenter study of patients with hypertension or arrhythmia treated with LDOM for any type of alopecia.
Background: Folliculitis decalvans (FD) is a rare primary neutrophilic scarring alopecia whose etiology has not been completely elucidated yet.
Objective: The aim of the study was to determine if the follicular microbiota residing in FD-affected hair follicles had a distinct microbiological signature and if an aberrant immune response was present in the pathogenesis of FD.
Methods: We conducted a cross-sectional study of 10 patients affected by FD.
Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.
Objectives: To study whether low-dose rituximab is also effective for bullous pemphigoid.
Methods: Patients with BP were treated with a single cycle of two infusions of rituximab 500 mg at an interval of 2 weeks.
Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris.
Objectives: To study whether low-dose rituximab is also effective for bullous pemphigoid.
Methods: Patients with BP were treated with a single cycle of two infusions of rituximab 500mg at an interval of 2 weeks.
Background: Pliaglis is a self-occluding topical anesthetic containing a eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and safety in several trials.
Aims: To evaluate the effectiveness and safety of Pliaglis for different dermatological procedures in real-life clinical practice.
Methods: This retrospective, multicenter study included 35 patients treated with Pliaglis prior to five dermatological procedures (pulsed dyed laser, picosecond laser, non-ablative fractional laser, radiofrequency microneedling, and photodynamic therapy).
A woman presented to the emergency department during the COVID-19 pandemic, reporting a slightly pruritic rash that had developed five days after the onset of fever, cough and malaise.
View Article and Find Full Text PDF